Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 10

586P - Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial

Date

21 Oct 2023

Session

Poster session 10

Topics

Clinical Research;  Cancer Diagnostics

Tumour Site

Colon and Rectal Cancer

Presenters

Daphne Day

Citation

Annals of Oncology (2023) 34 (suppl_2): S410-S457. 10.1016/S0923-7534(23)01935-X

Authors

D. Day1, A. Starus2, V. Gebski3, J. Simes3, T. Hayes4, S. Padinharakam5, A.H. Strickland1, K. Briscoe6, S. Varma7, M. Barnet8, C. Jackson9, L.G. Horvath10, T.J. Price11, N. Tebbutt12, B. Karki13, C.I. Diakos14, J.W.K. Chia15, H.C. Toh15, F.S. Jones2, E. Segelov16

Author affiliations

  • 1 Department Of Oncology, Monash Health and Department of Medicine, 3168 - Clayton/AU
  • 2 Medical Affairs, Sysmex-Inostics, Inc., 21201 - Baltimore/US
  • 3 Nhmrc Clinical Trial Centre, University of Sydney, 2006 - Sydney/AU
  • 4 Medical Oncology, Southwest Oncology, 3280 - Warrnambool/AU
  • 5 Specialist Care Australia, Launceston General Hospital, 7250 - Launceston/AU
  • 6 Medical Oncology, Mid North Coast Cancer Institute, 2450 - Coffs Harbour/AU
  • 7 Department Of Oncology, The Townsville Hospital, 4814 - Douglas/AU
  • 8 The Kinghorn Cancer Centre, St Vincent's Hospital, 2010 - Sydney/AU
  • 9 Medical Oncology Department, Dunedin Hospital, 9016 - Dunedin/NZ
  • 10 Medical Oncology, Chris O'Brien Lifehouse, 2050 - Camperdown/AU
  • 11 Medical Oncology, University of Adelaide and Lyell McEwin Hospital, 5112 - Elizabeth Vale/AU
  • 12 Department Of Oncology, Austin Health, 3084 - Heidelberg/AU
  • 13 Toowoomba Hospital Cancer Centre Services, Toowoomba General Hospital, 4350 - Toowoomba/AU
  • 14 Medical Oncology Department, Genesis Care North Shore, 2065 - St Leonards/AU
  • 15 Medical Oncology Department, NCCS - National Cancer Centre Singapore, 169610 - Singapore/SG
  • 16 Department Of Clinical Research, Faculty of Medicine, University of Bern, 3012 - Bern/CH

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 586P

Background

Although ctDNA is associated with MRD and recurrence in curatively treated CRC, implementation in clinical practice remains to be optimised. We evaluated the utility of a tumour naive ctDNA assay using serial prospectively collected plasma samples from the ASpirin for Dukes C and high risk Dukes B COLorecTal cancer trial (ASCOLT, NCT00565708), a large randomised phase III study of adjuvant aspirin.

Methods

Plasma samples were collected at baseline, 6 and 12 m in the Australian/ New Zealand cohort (n= 452). In a cohort of 118 pts matched by follow-up time (59 with recurrence [cases] and 59 non-recurrent [controls]), we used an ultra-sensitive ctDNA assay (SafeSEQ, Sysmex Inostics) for MRD detection. Cell pellets were analysed for mutations related to clonal haematopoiesis of indeterminate potential (CHIP). Results were correlated with recurrence and CEA.

Results

291 plasma samples (median 4.0 mL, median DNA 71.0 gen equiv/uL) were analysed (54/118 F; median age 68; 48 high risk stage II, 70 stage III; all had adjuvant chemotherapy; median follow-up 53.1 m). 59 pts recurred at median 12.4 m, of whom 32 had detectable ctDNA (sens 54%, Table). CEA sensitivity for detecting recurrence was 26%. Of the 27 pts with recurrence but no detectable ctDNA, 13 (48%) recurred >12 m after final sample collection. 8 pts without recorded recurrence had plasma mutations (CHIP analysis not available n = 3, all TP53). In multivariate analysis adjusting for known risk factors, ctDNA positivity was independently associated with recurrence (OR, 6.5; 95% CI, 2.2 – 18.9; p<0.001). Median time from 1st positive ctDNA to imaging detected recurrence was 7.9 m (range 0.2 – 40.2). ctDNA change over time and correlation with tumour sequencing will be presented. Table: 586P

Summary of ctDNA Data

Recurrence No recurrence Total
Positive ctDNA* at any time point 32 8 40
Negative ctDNA 27 51 78
Total 59 59
Sensitivity 54% Specificity 86%

*SafeSEQ 14 gene CRC MRD assay: AKT1, APC, BRAF, CTNNB1, ERBB3, FBXW7, KRAS, NRAS, PIK3CA, POLE, PPP2R1A, RNF43, SMAD4 and TP53

Conclusions

Tumour naïve, serial ctDNA detection within 1 year of adjuvant chemotherapy is independently associated with recurrence, noting limitations in sensitivity and specificity.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Australasian Gastro-Intestinal Cancer Trials Group and Royal Australasian College of Physicians Foundation.

Disclosure

A. Starus: Non-Financial Interests, Institutional, Member, Anna Starus is an employee of Sysmex Inostics, Inc: Sysmex Inostics. F.S. Jones: Non-Financial Interests, Institutional, Member, Frederick Jones is an employee of Sysmex Inostics, Inc.: Sysmex Inostics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.